Mild cognitive impairment in Parkinson's disease: Diagnosis and progression to dementia

Iván Galtier1, Antonieta Nieto1, Jesús N Lorenzo2

  • 1a School of Psychology , University of La Laguna , La Laguna , Tenerife , Spain.

Abstract

Insights

Mild cognitive impairment in Parkinson

Area of Science:

  • Neurology
  • Neuroscience
  • Gerontology

Background:

  • Mild cognitive impairment (MCI) is prevalent in non-demented Parkinson's disease (PD) patients, serving as a significant risk factor for dementia.
  • The Movement Disorder Society (MDS) recently established guidelines for diagnosing PD-MCI, yet research utilizing these criteria remains limited.
  • Characterizing PD-MCI and understanding its progression to dementia are crucial for patient management and therapeutic development.

Purpose of the Study:

  • To characterize mild cognitive impairment in Parkinson's disease (PD-MCI) using the MDS criteria.
  • To assess the progression of PD-MCI to dementia over a six-to-eight-year follow-up period.
  • To identify predictors for the progression of cognitive impairment in PD patients.

Main Methods:

  • The study enrolled 43 idiopathic Parkinson's disease patients and 20 healthy controls.
  • MDS Task Force criteria were applied for PD-MCI diagnosis.
  • Follow-up assessments were conducted six to eight years post-diagnosis to evaluate cognitive changes and dementia onset.

Main Results:

  • A comprehensive assessment (MDS Level 2) diagnosed PD-MCI in 60.5% of patients, versus 23.3% with a brief assessment (MDS Level 1).
  • Multiple cognitive domain impairment was observed in 96.2% of PD-MCI patients.
  • Dementia developed in 42.3% of PD-MCI patients during the follow-up period.

Conclusions:

  • The study validates the MDS PD-MCI criteria, indicating higher prevalence than previously reported.
  • PD-MCI is confirmed as a significant risk factor for the development of dementia in Parkinson's disease.
  • Neurological impairment (Hoehn and Yahr stage), education, and memory deficits predict cognitive decline and dementia progression.

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
702
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.8K